Japan approves CyberKnife System for extracranial use
Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted Shonin approval of the CyberKnife robotic radiosurgery system from Accuray for use in treatment of extracranial tumors, including tumors that move with respiration.
As a result of this approval, the CyberKnife System may be used in Japan to treat tumors anywhere in the body, including those in the spine, lung, liver, pancreas and prostate, according to the Sunnyvale, Calif.-based company.
“Japanese regulatory approval for these expanded indications is a noteworthy milestone for Accuray and significantly expands the potential for the CyberKnife System in Japan,” said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray. “Because customers in Japan have a long history of using the CyberKnife System for tumors in the head and neck, we are pleased that the benefits of extracranial radiosurgery will finally be realized by this important market.”
As a result of this approval, the CyberKnife System may be used in Japan to treat tumors anywhere in the body, including those in the spine, lung, liver, pancreas and prostate, according to the Sunnyvale, Calif.-based company.
“Japanese regulatory approval for these expanded indications is a noteworthy milestone for Accuray and significantly expands the potential for the CyberKnife System in Japan,” said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray. “Because customers in Japan have a long history of using the CyberKnife System for tumors in the head and neck, we are pleased that the benefits of extracranial radiosurgery will finally be realized by this important market.”